In a preclinical study, researchers at Children's Hospital of Philadelphia (CHOP) demonstrated a novel gene therapy with potentially increased effectiveness and safety for the treatment for ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

MARLBOROUGH, Mass., March 7, 2025 /PRNewswire/ -- Candela Corporation (Candela), a leading global medical aesthetic device company headquartered in Marlborough, MA, today announced the global ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Dissociative identity disorder (DID) treatment involves a combination of different therapies, psychiatric medications, and coping strategies. Previously known as multiple personality disorder or split ...